Prelude Capital Management’s Urovant Sciences Ltd. UROV Stock Holding History

Prelude Capital Management’s Portfolio UROV Stock Details UROV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-247,148	Closed	-$3.99M	–	1943
2020 Q4	$3.99M	Buy	+247,148	New	+$3.06M	0.1%	142
2020 Q1	–	Sell	-46	Closed	-$1K	–	2258
2019 Q4	$1K	Sell	46 -120	-72%	-$1.3K	﹤0.01%	1865
2019 Q3	$2K	Sell	166 -134	-45%	-$1.16K	﹤0.01%	1627
2019 Q2	$2K	Buy	300 +107	+55%	+$878	﹤0.01%	1589
2019 Q1	$2K	Sell	193 -26	-12%	-$267	﹤0.01%	1695
2018 Q4	$1K	Sell	219 -33,244	-99%	-$303K	﹤0.01%	1726
2018 Q3	$402K	Buy	+33,463	New	+$396K	0.02%	587

Prelude Capital Management's UROV Position: Q1 2021 in Review

Prelude Capital Management sold out of Urovant Sciences Ltd. (UROV) in Q1 2021, closing a stake of 247,148 shares — an estimated $3.99M sold.

Prelude Capital Management first reported a position in UROV in Q3 2018 and held it in 7 quarters. The position peaked at $3.99M in Q4 2020. 0 funds tracked by Wall St. Rank hold UROV as of Q1 2021.

Prelude Capital Management reported no remaining Urovant Sciences Ltd. position as of Q1 2021 after selling out during the quarter.
Prelude Capital Management sold 247,148 Urovant Sciences Ltd. shares in Q1 2021, an estimated $3.99M.
Prelude Capital Management first reported a position in Urovant Sciences Ltd. in Q3 2018 and held it in 7 quarters.
Prelude Capital Management's Urovant Sciences Ltd. position peaked at $3.99M in Q4 2020.
0 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q1 2021.

Based on Prelude Capital Management's 13F filing for Q1 2021, filed 17 May 2021.